Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT

Kundu, Parveen; Lata, Sneh; Sharma, Punit; Singh, Harmandeep; Malhotra, Arun; Bal, Chandrasekhar

doi:10.1007/s00259-014-2723-9

Cited by 26 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, in accordance with our results some lesions were detected only with SSTR PET/CT (20)(21)(22). Differences in lesion detection FIGURE 2.…”

Section: Discussionsupporting

confidence: 89%

“…Although almost all oxyphilic and poorly differentiated tumors were shown to express SSTR in these studies, 18 F-FDG PET/CT was superior to SSTR scintigraphy in most cases. Studies having performed more sensitive SSTR PET reported about 2 of 4 SSTR-positive oxyphilic carcinomas (22) or included only papillary and follicular carcinomas (20,21). In the latter 2 DTC subtypes, variable proportions of SSTR-positive tumors were described before.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, SSTR-binding PET tracers such as 68 Ga-DOTATOC were established in clinical routine. To our knowledge, only 3 studies have compared the diagnostic performance of 68 Ga-labeled SSTR analogs (DOTATOC, DOTA-NOC, DOTALAN PET/CT) with 18 F-FDG PET/CT in the staging of iodine-negative DTC so far (20)(21)(22). Padhy et al reported their initial experience of 68 Ga-DOTATATE PET/CT in identifying noniodine-avid/non-18 F-FDG-avid disease in patients with DTC (23).…”

mentioning

confidence: 99%

See 2 more Smart Citations

⁶⁸Ga-DOTATOC PET/CT in Patients with Iodine- and ¹⁸F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin

et al. 2016

View full text Add to dashboard Cite

This study evaluated the impact of 68 Ga-DOTATOC PET/CT in detecting recurrence or metastases in differentiated thyroid carcinoma (DTC) patients with elevated serum thyroglobulin and both negative radioiodine imaging and negative 18 F-FDG PET/CT. Methods: 68 Ga-DOTATOC PET/CT (CT without contrast, low-dose) was performed on average 6 wk after negative 18 F-FDG PET/CT (CT contrastenhanced, full-dose) in 15 consecutive radioiodine-negative DTC patients with elevated and rising thyroglobulin. Visual assessment of 68 Ga-DOTATOC PET/CT images used a 4-point scale for classification of lesions (0, no pathologic findings; 1, benign; 2, equivocal; 3, malignant). PET findings were correlated with the histologic subtype of tumor, levels of serum thyroglobulin, and morphologic findings on full-dose CT and neck ultrasound. Histology or clinical and imaging follow-up served as a reference standard. Analysis was performed on a patient and lesion basis. Results: 68 Ga-DOTATOC PET/CT was true-positive in 5 patients (10 tumor lesions) and was falsepositive in 1 patient. The rate of positive 68 Ga-DOTATOC PET/CT was significantly higher in poorly differentiated/oxyphilic carcinomas (4/4 patients) than in papillary (1/5) or follicular (0/6) tumors. Thyroglobulin levels tended to be higher in patients with tumor localization on 68 Ga-DOTATOC PET/CT, but differences were not significant. In 2 of 5 patients with true-positive findings on 68 Ga-DOTA-TOC PET/CT, CT alone but not ultrasound identified 2 of 10 tumor lesions, but in both patients 68 Ga-DOTATOC-PET/CT revealed further tumor lesions not detected on CT alone. Conclusion: 68 Ga-DOTATOC PET/CT should be considered in the case of negative 18 F-FDG PET/CT in radioiodine-negative DTC patients with elevated and rising thyroglobulin. Imaging with 68 Ga-DOTATOC appears promising especially in poorly differentiated and oxyphilic subtypes of DTC.

show abstract

“…Yet, in accordance with our results some lesions were detected only with SSTR PET/CT (20)(21)(22). Differences in lesion detection FIGURE 2.…”

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

⁶⁸Ga-DOTATOC PET/CT in Patients with Iodine- and ¹⁸F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Vice versa, 68 Ga-SSA PET/CT in cases presenting higher Ki-67 values (.50%), even if positive, will likely not affect management. The added value of 18 F-FDG in welldifferentiated NENs (G1 and G2) is still under debate, and no international consensus has been reached (49)(50)(51)(52)(53).…”

Section: Clinical Valuementioning

confidence: 99%

Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

et al. 2017

View full text Add to dashboard Cite

CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA category 1 credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through November 2020.68 Ga-DOTATATE PET/CT provides information on the location of somatostatin receptor-expressing tumors. Integrating this imaging data effectively in patient care requires the clinical history; the histopathology and biomarker information; and the grade, stage, and prior imaging results. Previous therapies and technical aspects of the study should be considered, given their ability to alter the interpretation of the images. This includes physiologic biodistribution of the radiotracer, as well as conditions that engender false-positive results. This article provides a guide to the performance and interpretation of 68 Ga-DOTATATE PET/CT and describes its role in the diagnostic algorithm of neuroendocrine neoplasms and its overall utility in their management.

show abstract

“…Iodine therapy following surgery may evidently lower recurrence rates (18). However, during the treatment process, sensitivity of tumor nidi or metastatic tumor tissue to iodine is decreased or lost entirely, which may be caused by de-differentiation (19). In cases of the greatest severity with the worst prognosis, methods as surgery, radiotherapy and chemotherapy may not be sufficient to successfully treat PDHC (20).…”

Section: Discussionmentioning

confidence: 99%

Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer

Fan

Liang

Liu

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of the present study was to clarify whether the cell penetrating peptide of sodium-iodide symporter (NIS) has an effect on the I-131 radiotherapy of thyroid cancer. Firstly, we combined the HIV-1 TAT peptide (a cell penetrating peptide, dTAT) and established a nanoparticle vector (dTAT NP) to study the delivery efficiency of this cell-penetrating strategy for tumor-targeted gene delivery. dTAT NP was transfected into cultured TPC-1 cells as a model to study the effects of I-131 radiotherapy on thyroid cancer. Reverse transcription-quantitative polymerase chain reaction and western blotting results showed that the mRNA and protein expression levels of NIS in the transfected TPC-1 cells were substantially higher than in the negative control cells. MTT and flow cytometric analyses demonstrated that the cell growth and apoptosis rates of the TPC-1 cells were significantly inhibited and activated, respectively, by treatment with dTAT NP. The results of DAPI staining showed that treatment with dTAT NP visibly increased the nuclear apoptosis rate of the TPC-1 cells. The effect of dTAT NP on TPC-1 cells was associated with the promotion of caspase-3 and downregulation of the PI3K/Akt signaling pathway. In summary, the present data provide a pre-clinical proof-of-concept for a novel gene delivery system that efficiently delivers NIS to the targeted cancer cells and presents a satisfactory efficacy. This approach may offer an effective strategy for improving thyroid cancer gene therapy.

show abstract

Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT

Cited by 26 publications

References 26 publications

⁶⁸Ga-DOTATOC PET/CT in Patients with Iodine- and ¹⁸F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin

⁶⁸Ga-DOTATOC PET/CT in Patients with Iodine- and ¹⁸F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin

Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer

Contact Info

Product

Resources

About

Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT

Cited by 26 publications

References 26 publications

68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin

68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin

Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer

Contact Info

Product

Resources

About

⁶⁸Ga-DOTATOC PET/CT in Patients with Iodine- and ¹⁸F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin

⁶⁸Ga-DOTATOC PET/CT in Patients with Iodine- and ¹⁸F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin

Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies